

Performance in Delivering Research Q1 2016/17

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial	Comments
14/SS/0049	143780	A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week, Phase 3 Study of Two Doses of EVP-6124 or Placebo in Subjects with Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication	8	8	15/05/2016	0	19/08/2015	Withdrawn By Sponsor	suspended then closed safety reasons
12/SC/0435	107849	Efficacy and Safety of 3 doses of S38093 (2,5 and 20mg) versus placebo in co-administration with donezepil (10mg/day) in patients with moderate Alzheimers Disease	4	6	01/04/2015	4	01/04/2015	Recruitment Finished	
12/NE/0410	111232	A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer's Disease	3	4	29/01/2016	4	08/09/2015	Recruitment Finished	last patient visit 08/08/
12/SC/0435	107849	Efficacy and Safety of 3 doses of S38093 (2,5 and 20mg) versus placebo in co-administration with donezepil (10mg/day) in patients with moderate Alzheimers Disease	4	6	01/04/2015	4	01/04/2015	Recruitment Finished	
13/WA/0271	135084	A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease	10	10	30/06/2016	1	30/06/2016	Recruitment Finished	

